Navigation Links
Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
Date:5/19/2009

clude, among other things, statements regarding clinical trials, regulatory approvals, competitive offerings and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to al
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
2. Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientifics TAXUS(R) Liberte(R) Stent
3. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
4. Clinical Data Reinforce Safety and Efficacy of Boston Scientifics Two Drug- Eluting Stent Platforms
5. New England Journal of Medicine Publishes Results from Boston Scientifics Landmark SYNTAX(TM) Trial
6. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
7. Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
8. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
9. Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
10. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
11. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , August 29, 2014 ... Oil Market by Extraction type (SFE, Cold Pressed, ... Personal Care, Pharmaceutical, Food Supplements, Fragrance, & Others) - ... MarketsandMarkets, defines and segments the Amaranth Seed Oil ... market size in terms of value. The Amaranth ...
(Date:8/29/2014)... --  Vittamed Corporation , a neurodiagnostics medical device company based ... T. (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, ... " Teo Forcht Dagi is an experienced ... venture capital," said Remis Bistras , President and CEO ... strategic, and entrepreneurial expertise to our Board." Dr. ...
(Date:8/29/2014)... 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a workshop ... New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists will ... that hyperspectral imaging can bring to examination procedures. ... Director of Product Development at ChemImage, will host ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... 16, 2011  Kensey Nash Corporation (NASDAQ: KNSY ) ... to enter into non-binding mediation in an attempt to resolve ... Angio-Seal vascular closure device, as well as other related claims. ... are currently to be paid, and should since 2007 have ...
...  Pharmasset, Inc. (Nasdaq: VRUS ) announced today ... QUANTUM Phase 2b trial of the guanine nucleotide analog ... containing PSI-938. There are 235 individuals with hepatitis C ... with PSI-938 alone or in combination with PSI-7977 or ...
Cached Medicine Technology:Kensey Nash to Enter Into Mediation with St. Jude Medical over Angio-Seal Contract Disputes 2Kensey Nash to Enter Into Mediation with St. Jude Medical over Angio-Seal Contract Disputes 3Kensey Nash to Enter Into Mediation with St. Jude Medical over Angio-Seal Contract Disputes 4Pharmasset Announces Intent to Amend QUANTUM Trial 2Pharmasset Announces Intent to Amend QUANTUM Trial 3
(Date:8/30/2014)... 30 August 2014: Transvenous lead extraction (TLE) is clinically ... data from the European Lead Extraction ConTRolled (ELECTRa) registry ... 2014 by Dr Maria Grazia Bongiorni, chair of the ... of cardiac implantable electronic devices (CIED) implant procedures has ... number of complications has increased and leads are often ...
(Date:8/30/2014)... August 30, 2014 Top10BestSEOHosting.com is ... researchers have announced that HostGator.com http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ... current market. Also, they has announced that Bluehost ... , Hostgator, one of the Top 10 ... of cheap Windows hosting, and it offers rich ...
(Date:8/30/2014)... 30, 2014 LiveStreamingFitness.com, a company dedicated to ... healthy lifestyle resources, is proud to announce it has been ... at home fitness solutions by ABC’s Good Morning America. ... on ABC’s Good Morning America, “Live Streaming Fitness is the ... your day by streamlining your workout…to boot camp at Life ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 McLeod's Sunset ... service auto repair shop with strong ties to the community ... is happy to announce they have been chosen by ... pick for auto repair. , Tim McLeod’s father, Norris ... Service sixty years ago. Although his son, Tim runs the ...
(Date:8/30/2014)... FL (PRWEB) August 30, 2014 Zensah®, the ... Camo Compression Leg Sleeve . The camo sleeves are ... Leg Sleeve collection. The camo line includes classic colors ... and magenta. , Known as tibial stress syndrome, shin ... of the lower leg. Swollen and irritated muscles, stress fractures, ...
Breaking Medicine News(10 mins):Health News:Transvenous lead extraction clinically successful in 98 percent of cases 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 3Health News:Top10BestSEOHosting.com: HostGator.com Is The Best Windows Hosting Supplier 2Health News:LiveStreamingFitness.com is New Trend In Fitness 2Health News:McLeod's Sunset Park Auto Service Celebrates 60 Years Honored with Best of South Tampa 2Health News:Camo Compression Leg Sleeves Provide Shin Splint Relief for Runners 2
... Education Office of the European Association of Urology is ... & Progress, to be held during the 24th Annual ... Education & Progress presents notable technological innovations in urological ... the diagnosis and therapy of diseases by using miniaturised ...
... a conversation this country desperately needs about how to reduce ... setting a goal of universal coverage and initiating a public ... right approach. His inclusive brand of leadership makes the ... us to heed the call and to pursue comprehensive reform ...
... 9.3 at United States and Canadian Academy of ... part of the Elekta Group and leading provider ... today announced the introduction of PowerPath version 9.3, ... be demonstrated at USCAP conference in Boston, March ...
... they think they,re better able to play sports, be ... -- Compared to glasses, contact lenses improve how children ... and their acceptance among friends, a study of 484 ... effect of spectacle wear on self-perception and the perception ...
... Inc. (NYSE: MED ) announced today that it ... for the period ended December 31, 2008 on Thursday, March ... Company will hold a conference call and web cast to ... a.m. ET.Interested parties can access the call by dialing (877) ...
... Medifast, Inc. (NYSE: MED ), a ... announced the appointment of John P. Daniels and Sr. ... With the addition of Mr. Daniels and Sr. ... of fourteen members, ten of which are classified as ...
Cached Medicine News:Health News:Education and progress at the 24th Annual EAU Congress in Stockholm 2Health News:Impac Software Introduces PowerPath(R) Version 9.3 AT USCAP 2Health News:Impac Software Introduces PowerPath(R) Version 9.3 AT USCAP 3Health News:Contact Lenses Boost Kids' Self-Image 2Health News:Medifast, Inc. to Announce Fourth Quarter and Fiscal Year 2008 Financial Results on Thursday, March 12, 2009 2Health News:Medifast, Inc. Announces Appointment of Two Additional Independent Board Members 2Health News:Medifast, Inc. Announces Appointment of Two Additional Independent Board Members 3Health News:Medifast, Inc. Announces Appointment of Two Additional Independent Board Members 4
... TheraSeed® Pd-103 implant is a combination of ... visibility that makes TheraSeed® treatment an ideal ... be confident that every TheraSeed® implant order ... which is required by clinicians who must ...
... designed to help you achieve one important ... procedure. All needles are engineered for exceptional ... for smooth entry and exit. A broad ... an ideal match with procedural needs and ...
... a combination of innovative design, consistently reliable ... I-125 implant an ideal choice for your ... every BrachySource I-125 implant order is backed ... required by clinicians who must meet the ...
... drainage from the ureteropelvic junction to the ... segment with no sideports prevents postoperative narrowing ... of the ureteral wall to the stent. ... one-time use. CAUTION: Periodic evaluation is advised; ...
Medicine Products: